ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VRPX Virpax Pharmaceuticals Inc

0.9478
0.3581 (60.73%)
Pre Market
Last Updated: 09:28:20
Delayed by 15 minutes
Share Name Share Symbol Market Type
Virpax Pharmaceuticals Inc NASDAQ:VRPX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.3581 60.73% 0.9478 0.9478 0.948 3,365,658 09:28:20

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

18/11/2024 3:23pm

GlobeNewswire Inc.


Virpax Pharmaceuticals (NASDAQ:VRPX)
Historical Stock Chart


From Oct 2024 to Nov 2024

Click Here for more Virpax Pharmaceuticals Charts.

Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants.

Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications, raised $5.0 million through the sale of shares of common stock and pre-funded warrants at a public offering price of $0.50 per share. The company intends to use the proceeds for ongoing activities, including its planned Investigational New Drug (IND) filing for its patented injectable “local anesthetic” liposomal technology, Probudur™, aimed at post-operative pain management. Additionally, funds will be allocated to marketing and advertising services provided by IR Agency LLC, as well as general corporate purposes.

“We are proud to have served as the sole placement agent in Virpax Pharmaceuticals’ public offering,” said John Lowry, CEO of Spartan Capital Securities. “Virpax’s innovative approach to non-opioid pain management has the potential to address critical unmet needs in post-operative pain care. We look forward to continuing to support the company’s efforts to advance its breakthrough technologies.”

Spartan Capital Securities was represented by Lucosky Brooker LLP, with Scott Linksy, Xiaofan Zhang, and Raymond Ressy serving as counsel. Virpax Pharmaceuticals was represented by Sichenzia Ross Ference Carmel LLP, with Ross Carmel and Benjamin Sklar acting as counsel.

About Spartan Capital Securities, LLC

Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients' financial goals.

For more information about Spartan Capital Securities, visit www.spartancapital.com.

Contact:Spartan Capital Securities, LLC45 Broadway, 19th FloorNew York, NY 10006investmentbanking@spartancapital.com

1 Year Virpax Pharmaceuticals Chart

1 Year Virpax Pharmaceuticals Chart

1 Month Virpax Pharmaceuticals Chart

1 Month Virpax Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock